Restricted accessResearch articleFirst published online 2019-3
Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis
The number of people living with HIV (PLWH) ≥65 years is increasing in the United States. By 2035, the proportion of PLWH in this age group is projected to be 27%. As PLWH live longer, they face age-related comorbidities. We compared non-HIV disease and medication burden among PLWH (n = 2359) and HIV-negative individuals (n = 2,010,513) ≥65 years using MarketScan® Medicare Supplemental health insurance claims from 2009 to 2015. Outcomes were common diagnoses and medication classes, prevalence of non-HIV conditions, number of non-HIV conditions, and daily non-antiretroviral therapy (ART) medications over a 1-year period. We examined age-standardized prevalence rates and prevalence ratios (PRs) and fit multivariable generalized linear models, stratified by sex. PLWH were younger (mean 71 vs. 76 years) and a larger proportion were men (81% vs. 45%). The most common diagnoses among both cohorts were hypertension and dyslipidemia. Most non-HIV conditions were more prevalent among PLWH. The largest absolute difference was in anemia (29.6 cases per 100 people vs.11.7) and the largest relative difference was in hepatitis C (PR = 22.0). Unadjusted mean number of non-HIV conditions and daily non-ART medications were higher for PLWH (4.61 conditions and 3.79 medications) than HIV-negative individuals (3.94 and 3.41). In models, PLWH had significantly more non-HIV conditions than HIV-negative individuals [ratios: men = 1.272, (95% confidence interval, 1.233–1.312); women = 1.326 (1.245–1.413)]. Among those with >0 daily non-ART medications, men with HIV had significantly more non-ART medications than HIV-negative men [ratio = 1.178 (1.133–1.226)]. The disease burden associated with aging is substantially higher among PLWH, who may require additional services to effectively manage HIV and comorbid conditions.
Get full access to this article
View all access options for this article.
References
1.
WardBW, SchillerJS, GoodmanRA. Multiple chronic conditions among US adults: A 2012 update. Prev Chronic Dis, 2014; 11:E62.
2.
GuQ, DillonCF, BurtVL. Prescription Drug Use Continues to Increase: U.S. Prescription Drug Data From 2007–2008. NCHS Data Brief, No 42. Hyattsville MD: National Center for Health Statistics. 2010. Available at: http://cdc.gov/nchs/data/databriefs/db42.pdf (Last accessed January15, 2019).
3.
Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: A collaborative analysis of cohort studies. Lancet HIV, 2017; 4:e349–e356.
4.
SchoutenJ, WitFW, StolteIG, et al.Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: The AGEhIV cohort study. Clin Infect Dis, 2014; 59:1787–1797.
5.
Rodriquez-PenneyAT, IudicelloJE, RiggsPK, et al.Co-morbidities in persons infected with HIV: Increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS, 2013; 27:5–16.
6.
GuaraldiG, ZonaS, BrothersTD, et al.Aging with HIV vs. HIV seroconversion at older age: A diverse population with distinct comorbidity profiles. PLoS One, 2015; 10:e0118531.
7.
GuaraldiG, OrlandoG, ZonaS, et al.Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis, 2011; 53:1120–1126.
8.
DeeksSG.HIV Infection, inflammation, immunosenescene, and aging. Annu Rev Med, 2011; 62:141–155.
9.
EscotaGV, O'HalloranJA, PowderlyWG, PrestiRM. Understanding mechanisms to promote successful aging in persons living with HIV. Int J Infect Dis, 2018; 66:56–64.
10.
HavlikRJ, BrennanM, KarpiakSE. Comorbidities and depression in older adults with HIV. Sex Health, 2011; 8:551–559.
11.
OnenNF, OvertonET, SeyfriedW, et al.Aging and HIV infection: A comparison between older HIV-infected persons and the general population. HIV Clin Trials, 2010; 11:100–109.
12.
HoltzmanC, ArmonC, TedaldiE, et al.Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med, 2013; 28:1302–1310.
13.
VanceDE, MugaveroM, WilliqJ, et al.Aging with HIV: A cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care, 2011; 22:17–25.
14.
SmitM, CassidyR, Cozzi-LepriA, et al.Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modeling study. PLoS One, 2017; 12:e0186638.
15.
WomackJA, ChangCC, So-ArmahKA, et al.HIV infection and cardiovascular disease in women. J Am Heart Assoc, 2014; 3:e001035.
16.
GiesbrechtCJ, ThorntonAE, Hall-PatchC, et al.Select neurocognitive impairment in HIV-infected women: Associated with HIV viral load, hepatitis C virus, and depression, but not leukocyte telomere length. PLoS One, 2014; 9:e89556.
17.
ValcourV, MakiP, BacchettiP, et al.Insulin resistance and cognition among HIV-infected and HIV-uninfected adult women: The Women's Interagency HIV study. AIDS Res Hum Retroviruses, 2012; 28:447–453.
18.
BaranoskiAS, HarrisA, MichaelsD, et al.Relationship between poor physical function, inflammatory markers, and comorbidities in HIV-infected women on antiretroviral therapy. J Womens Health (Larchmt). 2014; 23:69–76.
19.
CohenMH, HottonAL, HershowRC, et al.Gender-related risk factors improve mortality predictive ability of VACS Index among HIV-infected women. J Acquir Immune Defic Syndr, 2015; 70:538–544.
20.
DeyoRA, CherkinDC, CiolMA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol, 1992; 45:613–619.
21.
SteinmanMA, LeeSJ, BoscardinWJ, et al.Patterns of multimorbidity in elderly veterans. J Am Geriatr Soc, 2012; 60:1872–1880.
22.
LeeTA, ShieldsAE, VogeliC, et al.Mortality rate in veterans with multiple chronic conditions. J Gen Intern Med, 2007; 22:403–407.
23.
CornellJE, PughJA, WilliamsJW, et al.Multimorbidity clusters: Clustering binary data from multimorbidity clusters: Clustering binary data from a large clustering administrative medical database. Appl Multivariate Res, 2007; 12:163–182.
24.
LeslieRS. Calculating medication Compliance, Adherence, and Persistence in Administrative Pharmacy Claims Databases. 2016. Available at: https://pharmasug.org/download/sde/sd2016/PharmaSUG_SD2016SDE_07_Leslie.pdf (Last accessed January15, 2019).
25.
U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV: Limitations to Treatment Safety and Efficacy—Adverse Effects of Antiretroviral Agents. 2017. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/31/adverse-effects-of-arv (Last accessed January15, 2019).
26.
U.S. Department of Commerce, Economics and Statistics Administration U.S. Census Bureau. Census Regions and Divisions of the United States. 2015. Available at: https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf (Last accessed January15, 2019).
27.
U.S. Department of Commerce, Economics and Statistics Administration U.S. Census Bureau. Metropolitan Areas. In Geographic Areas Reference Manual. 2014. Available at: https://www2.census.gov/geo/pdfs/reference/GARM/Ch13GARM.pdf (Last accessed January15, 2019).
28.
GouletJL, FultzSL, RimlandD, et al.Aging and infectious diseases: Do patterns of comorbidity vary by HIV status, age, and HIV severity?. Clin Infect Dis, 2007; 45:1593–1601.
29.
PetoumenosK, HuangR, HoyJ, et al.Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian Positive and Peers Longevity Evaluation Study (APPLES). PLoS One, 2017; 12:e0184583.
30.
AlthoffKN, McGinnisKA, WyattCM, et al.Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis, 2015; 60:627–638.
31.
PaisibleAL, ChangCC, So-ArmahKA, et al.HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndrom, 2015; 68:209–216.
32.
FreibergMS, ChangCC, SkandersonM, et al.The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes, 2011; 4:425–432.
33.
RasmussenLD, MayMT, KronborgG, et al.Time trends for risk of severe age-related diseases in individuals with and without HIV infection in Denmark: A nationwide population-based cohort study. Lancet HIV, 2015; 2:e288–e298.
34.
GallantJ, HsuePY, ShreayS, MeyerN. Comorbidities among US patients with prevalent HIV infection–a trend analysis. J Infect Dis, 2017; 216:1525–1533.
35.
ShahASV, StelzleD, LeeKK, et al.Global burden of atherosclerotic cardiovascular disease in people living with HIV. Circulation, 2018; 138:1100–1112.
36.
SicoJJ, ChangCC, So-ArmahK, et al.HIV status and the risk of ischemic stroke among men. Neurology, 2015; 84:1933–1940.
37.
TripathiA, LieseAD, WinnifordMD, et al.Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. Clin Cardiol, 2014; 37:517–522.
38.
ParkLS, TateJP, Rodriguez-BarradasMC, et al.Cancer incidence in HIV-infected versus uninfected veterans: Comparison of cancer registry and ICD-9 code diagnoses. J AIDS Clin Res, 2014; 5:1000318.
39.
CrothersK, ButtAA, GibertCL, et al.Increased COPD among HIV-positive compared to HIV-negative veterans. Chest, 2006; 130:1326–1333.
40.
GreeneM, SteinmanMA, McNichollIR, ValcourV. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc, 2014; 62:447–453.
41.
MooreHN, MaoL, OramasionwuCU. Factors associated with polypharmacy and the prescription of multiple medications among persons living with HIV (PLWH) compared to non-PLWH. AIDS Care, 2015; 27:1443–1448.
42.
WareD, PalellaFJJr, ChewKW et al. Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016. PLoS One, 2018; 13:e0203890.
43.
Gimeno-GraciaM, Crusells-CanalesMJ, Armesto-GómezFJ, et al.Polypharmacy in older adults with human immunodeficiency virus infection compared with the general population. Clin Interv Aging, 2016; 11:1149–1157.
44.
GrossAM, JaegerPA, KreisbergJF, et al.Methylome-wide analysis of chronic HIV infection reveals five-year increase in biological age and epigenetic targeting of HLA. Mol Cell, 2016; 62:157–168.
45.
RickabaughTM, BaxterRM, SehlM, et al.Acceleration of age-associated methylation patterns in HIV-1-infected adults. PLoS One, 2015; 10:e0119201.
46.
GuaraldiG, PalellaFJJr. Clinical implications of aging with HIV infection: Perspectives and the future medical care agenda. AIDS, 2017; 31Suppl 2:S129–S135.
47.
WongC, GangeSJ, MooreRD, et al.Multimorbidity among persons living with HIV in the U.S. Clin Infect Dis, 2018:66:1230–1238.
48.
HentzienM, Dramé M, Allavena C, et al. Impact of age-related comorbidities on five-year overall mortality among elderly HIV-infected patients in the late HAART era—role of chronic renal disease. J Nutr Health Aging, 2016; 20:408–414.
49.
LangebeekN, KooijKW, WitFW, et al.Impact of co-morbidity and aging on health-related quality of life in HIV-positive and HIV-negative individuals. AIDS, 2017; 31:1471–1481.
50.
RichardsonK, AnanouA, LafortuneL, et al.Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging, 2011; 28:547–560.
51.
GnijdicD, HilmerSN, BlythFM, et al.Polypharmacy cutoff and outcomes: Five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol, 2012; 65:989–995.
52.
JyrkkaJ, EnlundH, KorhonenMJ, et al.Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging, 2009; 26:1039–1048.
53.
EspinoDV, BazalduaOV, PalmerRF, et al.Suboptimal medication use and mortality in an older adult community-based cohort: Results from the Hispanic EPESE Study. J Gerontol A Biol Sci Med Sci, 2006; 61:170–175.
54.
GandhiTK, WeingartSN, BorusJ, et al.Adverse drug events in ambulatory care. N Engl J Med, 2003; 348; 1556–1564.
55.
SmithJM, FlexnerC. The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. AIDS, 2017; 31:S173–S184.
56.
BurgessMJ, ZeuliJD, KastenMJ. Management of HIV/AIDS in older patients–drug/drug interactions and adherence to antiretroviral therapy. HIV AIDS (Auckl), 2015; 7:251–264.
57.
McNichollIR, GandhiM, HareCB, et al.A pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in older, HIV-positive patients. Pharmacotherapy, 2017; 37:1498–1506.
58.
MarzoliniC, BackD, WeberH, et al.Ageing with HIV: Medication use and risk for potential drug-drug interactions. J Antimicrob Chemother, 2011; 66:2107–2111.
59.
TsengA, SzadkowskiL, WalmsleyS, et al.Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother, 2013; 47:1429–1439.
60.
AbaraWE, AdekeyeOA, XuJ, et al.Correlates of combination antiretroviral adherence among recently diagnosed older HIV-infected adults between 50 and 64 years. AIDS Behav, 2016; 20:2674–2681.
61.
KrentzHB, GillMJ. The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients. AIDS Patient Care STDS, 2016; 30:11–17.
62.
BatchelderAW, GonzalezJS, BergKM. Differential medication nonadherence and illness beliefs in co-morbid HIV and type 2 diabetes. J Behav Med, 2014; 37:266–275.
63.
de ConinckZ, Hussain-AlkhateebL, BrattG, et al.Non-AIDS mortality is higher among successfully treated people living with HIV compared with matched HIV-negative control persons: A 15-year follow-up cohort study in Sweden. AIDS Patient Care STDS, 2018; 32:297–305.
64.
LadapoJA, RichardsAK, DeWittCM, et al.Disparities in the quality of cardiovascular care between HIV-infected versus HIV-uninfected adults in the United States: A cross-sectional study. J Am Heart Assoc, 2017; 6:pii: e007107
65.
LevyME, GreenbergAE, MagnusM, et al.Evaluation of statin eligibility, prescribing practices, and therapeutic responses using ATP III, ACC/AHA, and NLA dyslipidemia treatment guidelines in a large urban cohort of HIV-infected outpatients. AIDS Patient Care STDS, 2018; 32:58–69.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
